Moreover, 15% of them were taking LAMA or LABA therapies in combination ... approval and launch of the company's lead drug candidate into the large COPD market in late 2023 or 2024.
The CRYSTAL study is the first LABA/LAMA pragmatic ... from other COPD treatments, such as inhaled steroid-containing combination therapies," said Vasant Narasimhan, Global Head Drug Development ...
People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...
Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual ...
There are certain risk factors for COPD, including obesity and having type 2 diabetes. A new study has found that people who have type 2 diabetes who are treated with GLP-1 and SGLT-2 medications ...
News Medical on MSN9d
Diabetes medications may help lower COPD flare-up risk, study findsThe study reveals SGLT-2is are linked to fewer COPD exacerbations in type 2 diabetes, suggesting a need for further clinical ...
Patients with COPD had better inhaler adherence when invited to enroll in a program that lowers cost sharing for maintenance ...
The adjusted likelihood for an injurious fall in adults with COPD was elevated with a fall-risk increasing drug prescription, ...
The results of this comparative effectiveness research study suggest that sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback